Cargando…

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B

In patients with chronic hepatitis B (CHB), loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. However, HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg seroreversion are unknown. Using pooled data from three phase 3 clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lok, Anna S., Zoulim, Fabien, Dusheiko, Geoffrey, Chan, Henry L.Y., Buti, Maria, Ghany, Marc G., Gaggar, Anuj, Yang, Jenny C., Wu, George, Flaherty, John F., Subramanian, G. Mani, Locarnini, Stephen, Marcellin, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939500/ https://www.ncbi.nlm.nih.gov/pubmed/31909352 http://dx.doi.org/10.1002/hep4.1436

Ejemplares similares

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
por: Sonneveld, Milan J., et al.
Publicado: (2010)

Secreted hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection
por: Maslac, Olivia, et al.
Publicado: (2022)

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
por: Ahn, Sang Hoon, et al.
Publicado: (2018)

Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA
por: Ghany, Marc G., et al.
Publicado: (2022)

Genomic modeling of hepatitis B virus integration frequency in the human genome
por: Podlaha, Ondrej, et al.
Publicado: (2019)

Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients
por: Podlaha, Ondrej, et al.
Publicado: (2019)

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
por: Marcellin, Patrick, et al.
Publicado: (2012)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment
por: Wang, Kaifa, et al.
Publicado: (2020)

Towards the elimination and eradication of hepatitis B
por: Dusheiko, Geoffrey
Publicado: (2015)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
por: Buti, Maria, et al.
Publicado: (2014)

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India
por: Tamayo, Aracely, et al.
Publicado: (2016)

Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials
por: Tran, Tram T., et al.
Publicado: (2015)

Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues
por: Fan, Rong, et al.
Publicado: (2016)

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B
por: van Campenhout, Margo J. H., et al.
Publicado: (2020)

Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B
por: Brakenhoff, Sylvia M, et al.
Publicado: (2022)

Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B
por: Marcellin, Patrick, et al.
Publicado: (2020)

Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B
por: Nagata, Naruhiko, et al.
Publicado: (2016)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Bi, Jingfeng, et al.
Publicado: (2017)

Expression Pattern of Cytokines in Patients with Chronic Hepatitis B Receiving PEGinterferon Therapy
por: Chen, Shao-Long, et al.
Publicado: (2023)

Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B
por: van Buuren, Nicholas, et al.
Publicado: (2022)

Innate Antiviral Immune Responses to Hepatitis B Virus
por: Ait-goughoulte, Malika, et al.
Publicado: (2010)

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection
por: Revill, Peter A., et al.
Publicado: (2019)

Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study
por: Sonneveld, Milan J, et al.
Publicado: (2020)

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B
por: Roade, Luisa, et al.
Publicado: (2021)

Hepatitis B prevalence in pregnant women in China: Progress and realities
por: Dusheiko, Geoffrey
Publicado: (2021)

Elasomeran/peginterferon: Autoimmune hepatitis: case report
Publicado: (2022)

Hepatitis B Precore Protein: Pathogenic Potential and Therapeutic Promise
por: Walsh, Renae, et al.
Publicado: (2012)

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years
por: Buti, Maria, et al.
Publicado: (2015)

HBVdb: a knowledge database for Hepatitis B Virus
por: Hayer, Juliette, et al.
Publicado: (2013)

Origins and Evolution of the Primate Hepatitis B Virus
por: Locarnini, Stephen A., et al.
Publicado: (2021)

Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients
por: Lebossé, Fanny, et al.
Publicado: (2020)

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B
por: Wei, Lai, et al.
Publicado: (2018)

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
por: Kim, Yu Jin, et al.
Publicado: (2011)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis
por: Ying, Sang-Yu, et al.
Publicado: (2021)

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
por: Janssen, Harry L A, et al.
Publicado: (2023)

Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells
por: Aggarwal, Abhishek, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qg825lq5kdi29lgboim7ffr5hi